JHM Biopharmaceutical is an innovative biopharmaceutical enterprise dedicated to developing protein drugs and regenerative medical devices, whose core business focuses on three key areas: endocrinology, neurological disease treatment, and tissue repair. Leveraging years of R&D and industrialization experience, JHM Biopharmaceutical has established a comprehensive research system covering the entire product development lifecycle. With its core technological advantages, the enterprise has achieved internationally leading capabilities in scaling up its product pipeline and advancing industrialization. 

Not only does this successful Series C financing validate JHM Biopharmaceutical ‘s technological leadership, pipeline strategy, and industrialization capabilities, but it also positions the enterprise for accelerated growth in the years ahead. Looking ahead, JHM Biopharmaceutical will continue to leverage recombinant technology as its core innovative engine and advance the R&D and clinical development of its key pipeline assets. Guided by evolving market needs, the enterprise will further expand its product portfolio while accelerating industrialization and commercialization efforts. Through these initiatives, JHM Biopharmaceutical aims to strengthen its industry leadership and deliver innovative, high-quality therapeutic solutions to patients worldwide.

Dr. Chunsheng Leng, Founding Shareholder and Chief Scientist of JHM Biopharmaceutical, commented: “We sincerely appreciate the recognition and strong support from our investors in this financing round. JHM Biopharmaceutical has consistently focused on addressing unmet clinical needs, using our proprietary technology platforms as the engine of innovation. We have established a robust and competitive pipeline of recombinant protein therapeutics and medical devices and achieved key clinical milestones across several core programs. Going forward, we will accelerate clinical development and product translation to fully unlock the value of our pipeline and deliver more high-quality, breakthrough biologic therapies to patients and markets worldwide.” 

Qiantang Heda Industrial Fund: “As a key enterprise within Qiantang China Medical Port, JHM Biopharmaceutical’s development aligns closely with the regional industrial layout. Over the past five years, the enterprise has steadily advanced its pipeline and generated excellent clinical data. We are pleased to partner with such a high-quality local enterprise and remain confident in JHM Biopharmaceutical’s growth. Our participation represents an important strategic investment in recombinant protein therapeutics and medical devices, further strengthening the industrial ecosystem of Qiantang China Medical Port.” 

Harmony Invest: “JHM Biopharmaceutical has established an industry-leading full-process platform for recombinant protein therapeutics and medical devices, with competitive advantages in multiple core technologies. The enterprise’s product pipeline meets multi-dimensional market demand for high-end products, and the core team demonstrates efficiency, pragmatism, and rich industrialization experience. We believe JHM Biopharmaceutical is poised for a successful future.” 

Chengshu Capital: “We are honored to participate in this financing round and witness JHM Biopharmaceutical entering a new stage of growth. We highly recognize JHM Biopharmaceutical’s leading positioning in recombinant protein therapeutics and medical devices. Led by Dr. Leng Chunsheng, the team has pursued high-quality innovation for years. We believe JHM Biopharmaceutical, with its differentiated technology and clear commercialization path, has the potential to become a benchmark enterprise in China’s specialized biopharmaceutical sector. We will continue to collaborate closely with JHM Biopharmaceutical to support its high-quality growth and create long-term value together.” 

WinXCapital: “WinXCapital is proud to be a long-term partner of JHM Biopharmaceutical and to support the enterprise’s growth journey. As an active player in the hot field of recombinant protein therapeutics and medical devices, JHM Biopharmaceutical has built a high-quality product pipeline combining innovative core technologies with market potential. We are confident that with the support of all shareholders, the enterprise will achieve leapfrog development and become an industry benchmark, delivering innovative biopharmaceutical solutions to patients worldwide.” 

About the Investors

– Qiantang Heda Industrial Fund: Qiantang Heda Industrial Fund is a key innovation-focused investment entity in Qiantang (New) District, operated by Heda Financial Services under Qiantang Industrial Group and affiliated private fund managers. Established nine years ago, the fund has leveraged professional investment expertise to support the biopharmaceutical industry, promoting the full lifecycle development of local enterprises and fostering a robust capital ecosystem for regional innovation. 

– Harmony Invest: Harmony Invest is a professional venture capital firm with nearly 20 years of investment experience, focusing on health, biomedicine, and TMT sectors. With the support from Harmony Invest, the enterprise provides financial and value-added services to portfolio companies, covering four business lines: medical biopharma, health, technology innovation, and PE equity investments. To date, Harmony Invest has invested in over 70 companies, aiming to be a specialized investor in niche sectors.

– Chengshu Capital: Chengshu Capital focuses on early and growth-stage investments in medical devices and life sciences. Its management team consists of pioneers in China’s capital market and medical equity investment, with rich industry resources and experience. Chengshu Capital adheres to the philosophy of “focus, growth, long-term,” supporting companies at critical growth stages and co-creating long-term sustainable value.